These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study. Wang W; Wu Q; Yang J; Dong K; Chen X; Bai X; Chen X; Chen Z; Viboud C; Ajelli M; Yu H BMJ; 2020 Dec; 371():m4704. PubMed ID: 33323388 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges. Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824 [TBL] [Abstract][Full Text] [Related]
6. COVID-19: vaccination problems. Brüssow H Environ Microbiol; 2021 Jun; 23(6):2878-2890. PubMed ID: 33928745 [TBL] [Abstract][Full Text] [Related]
7. Time-varying optimization of COVID-19 vaccine prioritization in the context of limited vaccination capacity. Han S; Cai J; Yang J; Zhang J; Wu Q; Zheng W; Shi H; Ajelli M; Zhou XH; Yu H Nat Commun; 2021 Aug; 12(1):4673. PubMed ID: 34344871 [TBL] [Abstract][Full Text] [Related]
8. The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials. Rid A; Lipsitch M; Miller FG JAMA; 2021 Jan; 325(3):219-220. PubMed ID: 33315080 [No Abstract] [Full Text] [Related]
9. Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations. Botton J; Semenzato L; Jabagi MJ; Baricault B; Weill A; Dray-Spira R; Zureik M JAMA Netw Open; 2022 Mar; 5(3):e220868. PubMed ID: 35234883 [TBL] [Abstract][Full Text] [Related]
11. The variants of SARS-CoV-2 and the challenges of vaccines. Han X; Ye Q J Med Virol; 2022 Apr; 94(4):1366-1372. PubMed ID: 34890492 [TBL] [Abstract][Full Text] [Related]
12. COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts. Rashedi R; Samieefar N; Masoumi N; Mohseni S; Rezaei N J Med Virol; 2022 Apr; 94(4):1294-1299. PubMed ID: 34796525 [TBL] [Abstract][Full Text] [Related]
13. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months. Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972 [TBL] [Abstract][Full Text] [Related]
14. Metabolic disorders, COVID-19 and vaccine-breakthrough infections. Stefan N Nat Rev Endocrinol; 2022 Feb; 18(2):75-76. PubMed ID: 34873287 [TBL] [Abstract][Full Text] [Related]
15. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't. Malek AE; Cornejo PP; Daoud N; Alam M Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190 [No Abstract] [Full Text] [Related]
16. Vaccination and COVID-19 Dynamics in Dialysis Patients. El Karoui K; Hourmant M; Ayav C; Glowacki F; Couchoud C; Lapidus N; Clin J Am Soc Nephrol; 2022 Mar; 17(3):395-402. PubMed ID: 35144970 [TBL] [Abstract][Full Text] [Related]
17. Impact of SARS-CoV-2 vaccines on Covid-19 incidence and mortality in the United States. Fang F; Clemens JD; Zhang ZF; Brewer TF PLoS One; 2024; 19(4):e0301830. PubMed ID: 38656933 [TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccine access in Africa: Global distribution, vaccine platforms, and challenges ahead. Massinga Loembé M; Nkengasong JN Immunity; 2021 Jul; 54(7):1353-1362. PubMed ID: 34260880 [TBL] [Abstract][Full Text] [Related]
19. Vaccine Effectiveness against SARS-CoV-2 among Household Contacts during Omicron BA.2-Dominant Period, Japan. Ogata T; Tanaka H; Kon A; Sakaibori N; Tanaka E Emerg Infect Dis; 2024 Jul; 30(7):1430-1433. PubMed ID: 38916601 [TBL] [Abstract][Full Text] [Related]